Literature DB >> 10492059

Dextromethorphan O-demethylation polymorphism in an African-American population.

N He1, H I Daniel, L Hajiloo, D Shockley.   

Abstract

OBJECTIVE: One hundred eighty-one (97 F, 84 M) unrelated healthy African-American subjects (aged 18-41 years) were phenotyped based on their dextromethorphan (DMP) O-demethylation ability.
METHODS: Each subject was given 15 mg DMP orally and collected 8-h urine. The concentrations of DMP and its metabolite dextrophan (DOP) were determined by HPLC with ultraviolet detection. Metabolic ratio (MR) was expressed as the ratio of DMP to DOP molar amount in urine.
RESULTS: The frequency distribution histogram of the MR was bimodal, and probit analysis of this frequency gave an antimode value of 0.34. Seven subjects [3.9%, 95% confidence interval (CI) 1.1%-6.7%] were classified as poor metabolizers (PMs).
CONCLUSION: This deficient frequency is in complete agreement with the reported ones in two smaller investigations in the African-American populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10492059     DOI: 10.1007/s002280050656

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  Genetic polymorphism of CYP2D6 in Tamil population.

Authors:  B K Abraham; C Adithan; J Mohanasundaram; C H Shashindran; K Koumaravelou; M Asad
Journal:  Eur J Clin Pharmacol       Date:  2001 Jan-Feb       Impact factor: 2.953

2.  Dextromethorphan metabolic phenotyping in an Iranian population.

Authors:  Minoo Afshar; Mohammadreza Rouini; Shahram Ala
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

3.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.